Reuters logo
BRIEF-ACIP votes 8-7 to prefer GSK's shingles vaccine Shingrix over Merck's Zostavax
2017年10月25日 / 下午3点11分 / 1 个月前

BRIEF-ACIP votes 8-7 to prefer GSK's shingles vaccine Shingrix over Merck's Zostavax

Oct 25 (Reuters) - Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP), responsible for U.S. vaccination schedules:

* Votes 8-7 to give GlaxoSmithKline’s Shingrix preferential recommendation over Merck’s Zostavax

Further company coverage: (Reporting by UK bureau)

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below